Structural variation manipulates the differential oxidative susceptibility and conformational stability of apolipoprotein E isoforms

Proteins: Structure, Function and Genetics

Volumn 68, Issue 1, 2007, Pages 363-374

  Su, Kuo Liang ^a   Wen, Ta Hsiang ^a   Chou, Chi Yuan ^b   Chang, Gu Gang ^b   Liu, Guang Yaw ^c   Hung, Hui Chih ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Analytical untracentrifuge; Fluorescence; Protein oxidation; Protein stability; Quaternary structure

Indexed keywords

APOLIPOPROTEIN E;

AMINO ACID SUBSTITUTION; ARTICLE; FLUORESCENCE SPECTROSCOPY; HUMAN; MOLECULAR WEIGHT; OXIDATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN STABILITY; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; ULTRACENTRIFUGATION;

APOLIPOPROTEINS E; CIRCULAR DICHROISM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; MUTAGENESIS, SITE-DIRECTED; OXIDATIVE STRESS; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN ISOFORMS; SPECTROMETRY, FLUORESCENCE; ULTRACENTRIFUGATION;

EID: 34249874067     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21443     Document Type: Article

References (67)

1. Lalazar A, Mahley RW. Human apolipoprotein E. Receptor binding activity of truncated variants with carboxyl-terminal deletions. J Biol Chem 1989;264:8447-8450.
2. Demant T, Bedford D, Packard CJ, Shepherd J. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. J Clin Invest 1991;88:1490-1501.
3. Dong LM, Wilson C, Wardell MR, Simmons T, Mahley RW, Weisgraber KH, Agard DA. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem 1994:269:22358-22365.
4. Kao JT, Tsai KS, Chang CJ, Huang PC. The effects of apolipoprotein E polymorphism on the distribution of lipids and lipoproteins in the Chinese population. Atherosclerosis 1995;114:55-59.
5. Siest G, Pillot T, Regis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau MM, Visvikis S. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 1995;41:1068-1086.
6. Dong LM, Weisgraber KH. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem 1996;271:19053-19057.
7. Weisgraber KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994;45:249-302.
8. Weisgraber KH. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res 1990;31:1503-1511.
9. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982;257:2518-2521.
10. Mahley RW, Huang Y, Rall SC, Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J Lipid Res 1999;40:1933-1949.
11. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:8098-8102.
12. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 1994;269:23403-23406.
13. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994;264:850-852.
14. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 1994;94:860-935.
15. Henderson AS, Easteal S, Jorm AF, Mackinnon AJ, Korten AE, Christensen H, Croft L, Jacomb PA. Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet 1995;346:1387-1390.
16. Pericak-Vance MA, Haines JL. Genetic susceptibility to Alzheimer disease. Trends Genet 1995;11:504-508.
17. Schellenberg GD. Genetic dissection of Alzheimer disease, a heterogeneous disorder. Proc Natl Acad Sci USA 1995;92:8552-8559.
18. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995;92:4725-4727.
19. Baum L, Chen L, Ng H-K, Pang CP. Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology. Microsc Res Tech 2000;50:278-281.
20. Buttini M, Akeefe H, Lin C, Mahley RW, Pitas RE, Wyss-Coray T, Mucke L. Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience 2000;97:207-210.
21. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
22. Saunders AM, Strittmatter WJ, Goldgarb D, Schmechel D, St. George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurobiology 1993;43:1467-1472.
23. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342:697-699.
24. Corder EH, Saunders AM, Strittmatter MJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
25. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
26. Nolte RT, Atkinson D. Conformational analysis of apolipoprotein A-I and E-3 based on primary sequence and circular dichroism. Biophys J 1992;63:1221-1239.
27. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991;252:1817-1822.
28. Wilson C, Mau T, Weisgraber KH, Wardell MR, Mahley RW, Agard DA. Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein. Structure 1994;2:713-718.
29. Westerlund JA, Weisgraber KH. Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J Biol Chem 1993;268:15745-15750.
30. Leininger-Muller B, Jolivalt C, Bertrand P Siest G. Oxidation of human apolipoprotein E and cerebral enzymatic systems. Alzheimer's Rep 1998;1:95-99.
31. Castano EM, Prelli F, Pras M, Frangione B. Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L. Implications for amyloidogenesis and Alzheimer's disease. J Biol Chem 1995;270:17610-17615.
32. Marques MA, Tolar M, Harmony JAK, Crutcher KA. A thrombin cleavage fragment of apolipoprotein E exhibits isoform specific neurotoxicity. Neuroreport 1996;7:2529-2532.
33. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nature Genet 1996;14:55-61.
34. Pedersen WA, Chan SL, Mattson MP. A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J Neurochem 2000;74:1426-1433.
35. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong L, Jakes R, Huang DY, Pericak-Vance M, Schmechel D, Roses AD. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer's disease. Proc Natl Acad Sci USA 1994;91:11183-11186.
36. Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Mol Brain Res 1995;33:174-178.
37. Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med 1980;203:1283-1291.
38. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-890.
39. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992;135:235-239.
40. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991;541:163-166.
41. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci USA 2001;98:8838-8843.
42. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, Weisgraber KH, Mucke L, Mahley RW, Huang Y. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA 2003;100:10966-10971.
43. Leininger-Muller B, Jolivalt C, Pillot T, Lagrange P, Livertoux MH, Grassiot MC, Minn A, Siest G. Apolipoprotein E and Alzheimer's disease. In: Roses AD, Weisgraber KH, Christen Y, editors. Research and perspectives in Alzheimer's disease. Paris: Springer-Verlag; 1995. pp 161-169
44. Jolivalt C, Leininger-Muller B, Drozdz R, Naskalski JW, Siest G. Apolipoprotein E is highly susceptible to oxidation by myeloperoxidase, an enzyme present in the brain. Neurosci Lett 1996;210:61-64.
45. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc Natl Acad Soc USA 1994;91:3270-3274.
46. Jolivalt C, Leininger-Muller B, Bertrand P, Herber R, Christen Y, Siest G. Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids. Free Radic Biol Med 2000;28:129-140.
47. Stohs SJ, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med 1995;18:321-336.
48. Fenton HJH. Oxidation of tartaric acid in the presence of iron. J Chem Soc 1894;65:899-910
49. Koppenol WH. The centennial of the Fenton reaction. Free Radic Biol Med 1993;15:645-651.
50. Sanchez del Pino MM, Fersht AR. Nonsequential unfolding of the α/β barrel protein indole-3-glycerol-phosphate synthase. Biochemistry 1997;36:5560-5565.
51. Pace CN. Determination and analysis of urea and guanidine hydrochloride denaturation curves. Methods Enzymol 1986;131:266-280.
52. Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. Biophys J 2000;78:1606-1619.
53. Schuck P, Perugini MA, Gonzales NR, Howlett GJ, Schubert D. Size distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. Biophys J 2002;82:1096-1111.
54. Morrow JA, Segall ML, Lund-Katz S, Phillips MC, Knapp M, Rupp B, Weisgraber KH. Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Biochemistry 2000;39:11657-11666.
55. Chou CY, Lin YL, Huang YC, Sheu SY, Lin TH, Tsay HJ, G Chang GG, Shiao MS. Structural variation in human apolipoprotein E3 and E4: secondary structure, tertiary structure and size distribution. Biophys J 2005;88:455-466.
56. Chou CY, Jen WP, Hsieh YH, Shiao MS, Chang GG. Structural and functional variations in human apolipoprotein E3 and E4. J Biol Chem 2006;281:13333-13344.
57. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-147.
58. Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 1990;55:342-345.
59. Balazs L, Leon M. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem Res 1994;19:1131-1137.
60. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T, Smith MA, Perry G, Yen SH, Stern D. Glycated tau protein in Alzheimer's disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994;91:7787-7791.
61. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995;45:1594-1601.
62. Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomom RG, Smith MA. 4-HNE-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997;68:2092-2097.
63. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609-1623.
64. Wetterau JR, Aggerbeck LP, Rall SC, Jr, Weisgraber KH. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem 1988;263:6240-6248.
65. Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu ,C-S, Lindgren FT. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem 1988;263:6249-6258.
66. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995;8:127-134.
67. Dong LM, Parkin S, Trakhanov SD, Rupp B, Simmons T, Arnold KS, Newhouse YM, Innerarity TL, Weisgraber KH. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol 1996;3:718-722.